India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…

India’s Wockhardt saw its losses widen last year as its burgeoning regulatory issues with the FDA continue to chainsaw away at its finances.

Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…

India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

China’s Kangmei Pharma, a company focused on oral traditional Chinese medicine, intends to pour $146 million into a healthcare industry fund.

Perrigo, which is under pressure from investors to shore up its finances, will raise a little cash with a deal to sell an API plant to India’s Strides Shasun.

Takeda says its new oral multiple myeloma drug Ninlaro is on course to become its biggest-ever cancer product.

Daiichi Sankyo licenses two abuse-deterrent painkillers from Inspirion to further its pain-management ambitions.

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…

AstraZeneca has licensed diabetes drugs Byetta and Bydureon to 3SBio to kickstart sales growth in China.

Financials